SCHEMBL3349063

SCHEMBL3349063

CCCCN1CCOc2c(-c3ncco3)cc(C(=O)OC)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA3 O75311 1/20 0.40
GLRB P48167 1/20 0.40
CFTR P13569 1/20 0.36
KDM4C Q9H3R0 2/20 0.35
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
JMJD6 Q6NYC1 1/20 0.34
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
DRD2 P14416 2/20 0.32
HTR4 Q13639 4/20 0.32
CYSLTR2 Q9NS75 1/20 0.31
CYSLTR1 Q9Y271 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
CYP3A4 P08684 1/20 0.31
CASP3 P42574 1/20 0.31
CYP2C9 P11712 1/20 0.31
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13306389 0.97 GLRA3 (0.39) GLRA3GLRBCFTRKDM4CKDM5A
SCHEMBL3350595 0.89 RARB (0.34) KDM4CKDM5AKDM5BJMJD6DRD2
SCHEMBL13306391 0.87 RARB (0.37) KDM4CKDM5AKDM5BJMJD6CYSLTR2
SCHEMBL6044403 0.81 LMNA (0.37) ROCK2DRD2CYSLTR2CYSLTR1HTR1A
SCHEMBL3350806 0.79 SMN1; SMN2 (0.42) DRD2HTR4CYP2C9CHRM2CHRM4
SCHEMBL3350982 0.79 HTR4 (0.40) DRD2HTR4CYSLTR2CYSLTR1CYP3A4
SCHEMBL6044266 0.78 BACE1 (0.38) ROCK2
SCHEMBL3350535 0.76 HTR4 (0.43) HTR4CYP3A4CYP2C9CHRM2CHRM4
SCHEMBL13306385 0.76 MGLL (0.39) HTR4CYSLTR2CYSLTR1CYP2C9KDM4E
SCHEMBL3348964 0.72 BACE1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 GLRA3 329/4885GLRB 233/4885CFTR 4302/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP GLRA3 502/4885GLRB 184/4885CFTR 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.